DC2020: Li Zi pay, cerebrovascular interventional treatment progress.

On September 17-18, 2020, the 10th China Medical Device Summit (DeviceChina2020), jointly organized by BioBAY and the China Medical Device Industry Association, was held at Suzhou International Expo Center.
This year, the Forum to "pick up the grade, the new journey" as the theme, continue to pay attention to China's medical device industry ecological development, the latest changes in industry policy;
on September 18th, Li Zihua, deputy director of Shanghai Changhai Hospital, delivered a speech on the theme of "Progress in Cerebrovascular Interventional Therapy".
, deputy director of Shanghai Changhai Hospital, said that from the clinician's point of view, the interventional treatment of cerebrovascular disease will play a guiding role in the later research and development.
cerebrovascular disease began a hundred years ago, when angiosis was carried out around the problem of intracranial tumors, originally intended to see how the tumor was stained and occupied, inadvertently opening the door to the treatment of cerebrovascular disease.
50s, first broke with the original traditional treatment, for cervical artery stenosis, by blocking or ligation, the inside of the plaque peeled out, and then re-stitched the blood vessels, this is an update of the concept, a very ground-breaking work.
1979, the use of balloons to treat the arteries in the neck was also a very good way.
but CEA has a monopoly, is a gold standard, then the balloon molding and stent molding this new treatment compared to CE is equally advantageous? A large number of clinical trials have shown that CAS and CEA are equal in efficacy, and more studies will follow to support CAS, especially in China.
of cervical artery stenosis requires treatment, which method is used to treat it? Li Zi fu stressed that both methods have their own adaptive disorders, in a short period of time, it is difficult to replace the other way, who will win in a short period of time is difficult to say, they all have a reason to exist, for business investment, there may be some risk.
neck artery stent is now mature, from the enterprise's point of view is difficult to insert, may only be able to do imitation, then where is our future direction? Over the years the department of cardiovascular medicine published a lot of articles, also confirmed its significance, Li Zifu said: "I believe that after the cervical artery ultrasound, including we are now very popular arterial flow blood flow-oriented stent, can be very good treatment, this is a direction, as long as these ultrasound things more nuanced, you can use the cerebrovascular, and its market is very large, this is the cervical artery for the enterprise significance."
Li Zifu reviewed the troubled course of ischemic stroke relief, he said: "In 1999, found that some patients with thrombolytic blood vessels insoluble, then use arteries to dissolve this thrombosis, found that his bleeding rate also increased, and then thought whether it can be used to remove this thrombosis?" A bolt-picker machine has since emerged and has been improving.
then the bracket appeared.
" on the treatment of aneurysms, Li Zi fu explained: "There are two main treatment methods, the first is interventional treatment, the second is open cranial clamping, can open cranial clamping can also choose interventional treatment, but not all aneurysms can be involved in treatment, each product has its own more biased adaptation, but overall, we see the trend is now aneurysm clamping less and less, therefore, only master the trend, the development of our enterprise will not be more and more difficult."
" Li Zifu stressed that ischemic stroke is our country's current top priority prevention and control projects, we will certainly encounter many problems in the process of treating stroke, better solve these problems will promote better product improvement, better update of ideas.
if an enterprise wants to continue to develop rapidly or lead the development of enterprises, it must work with clinical centers to finally create better products.
Bio-Discovery Source: Bio-Discovery Copyright Notice: All text, images and audio-visual materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.